CJC-1295 / Ipamorelin
A popular combination for raising growth hormone. Each peptide has limited human data, and the combination has none.
Quick chart
Change these and every table below updates.
Dosing schedules (as studied)
Both schedules come from the 2006 repeat-dose study of CJC-1295 alone in healthy adults. Doses were set per kilogram of body weight, so pick a weight above to see the amount in mg. These were short studies of two or three injections, not long-term regimens.
Every two weeks
Biweekly groupsTwo injections, 14 days apart. One group received 30 mcg/kg and another 60 mcg/kg. The 30 mcg/kg dose is shown.
| Phase | Day | Dose per injection | Syringe units | Volume | Doses per vial* |
|---|---|---|---|---|---|
| Injection 1 | Day 0 | 30 mcg/kg = 2.45 mg at 180 lb |
49 | 0.49 mL | 2 |
| Injection 2 | Day 14 | 30 mcg/kg = 2.45 mg at 180 lb |
49 | 0.49 mL | 2 |
* Limited by the vial's contents or the 28-day use limit after mixing, whichever comes first.
IGF-1 stayed above baseline for up to 28 days after repeat doses.
- 1 × 10 mg vials (each vial is used for at most 28 days after mixing)
- 2 mL bacteriostatic water (2 mL per vial)
- 2 × 0.5 mL (50-unit) U-100 insulin syringes
- 5 alcohol prep pads, plus a sharps container
Weekly
Weekly groupsThree injections, 7 days apart. One group received 20 mcg/kg and another 30 mcg/kg. The 30 mcg/kg dose is shown.
| Phase | Day | Dose per injection | Syringe units | Volume | Doses per vial* |
|---|---|---|---|---|---|
| Injection 1 | Day 0 | 30 mcg/kg = 2.45 mg at 180 lb |
49 | 0.49 mL | 4 |
| Injection 2 | Day 7 | 30 mcg/kg = 2.45 mg at 180 lb |
49 | 0.49 mL | 4 |
| Injection 3 | Day 14 | 30 mcg/kg = 2.45 mg at 180 lb |
49 | 0.49 mL | 4 |
* Limited by the vial's contents or the 28-day use limit after mixing, whichever comes first.
Drug levels built up with weekly dosing, peaking 29–70% higher after the third injection than after the first.
- 1 × 10 mg vials (each vial is used for at most 28 days after mixing)
- 2 mL bacteriostatic water (2 mL per vial)
- 3 × 0.5 mL (50-unit) U-100 insulin syringes
- 7 alcohol prep pads, plus a sharps container
Reconstitution for this setup
- Let the 10 mg vial reach room temperature and wipe both stoppers with alcohol.
- Slowly add 2 mL of bacteriostatic water, aiming down the inside wall of the vial.
- Swirl gently until clear. Never shake.
- Label the vial: 5 mg/mL, with today's date. Refrigerate and use within 28 days.
Study details
| Study | Dose | Schedule |
|---|---|---|
| Study 1 (single dose) | 30, 60, 125 or 250 mcg/kg | One injection under the skin |
| Study 2 (repeat doses) | 30 or 60 mcg/kg | Two injections, 14 days apart |
| Study 2 (repeat doses) | 20 or 30 mcg/kg | Three injections, 7 days apart |
- The authors reported the drug was best tolerated at 30 or 60 mcg/kg.
- Growth hormone and IGF-1 stayed raised for days after each dose, with a cumulative effect after repeat doses.
- Clinical development of CJC-1295 did not continue.
Research summary
CJC-1295 mimics growth-hormone-releasing hormone. Ipamorelin mimics ghrelin. Together they are meant to raise the body's own growth hormone release.
What the research shows
- A 2006 human study found that CJC-1295 raised growth hormone and IGF-1 levels for days after one dose. Clinical development did not continue.
- Ipamorelin reached Phase 2 for post-surgical bowel recovery but did not meet its goal.
- No trials have tested the two together.
Regulatory status
The FDA placed both CJC-1295 and ipamorelin in compounding Category 2 in 2023, citing safety concerns.
References
- Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab 2006;91(3):799–805. View source
Related compounds
Last reviewed: November 2026